Dr. Reddy's Laboratories Limited has announced about the conclusion of the patent litigation brought by Indivior Inc. ("Indivior Inc.") and Indivior UK Limited, ("Indivior UK," and together with Indivior Inc., "Indivior") and Aquestive Therapeutics, Inc. ("Aquestive") relating to the Company's generic buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages, a therapeutic equivalent generic version of Suboxone® sublingual film in U.S.A. On June 28, 2022 the U.S. Court dismissed all claims and counterclaims pending in the case with prejudice, pursuant to a joint stipulation of dismissal filed by the parties. The stipulation of dismissal was filed pursuant to a settlement agreement that the Company entered into with Indivior and Aquestive. The settlement and dismissal resolves all claims between the parties, including Indivior's and Aquestive's claims for patent infringement as well as the Company's antitrust counterclaim against Indivior.
Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 4363.30 as compared to the previous close of Rs. 4374.65. The total number of shares traded during the day was 9625 in over 1859 trades.
The stock hit an intraday high of Rs. 4406.45 and intraday low of 4335.75. The net turnover during the day was Rs. 42078053.00. |
